Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03348748 · ClinicalTrials.gov registry record · Early Phase 1
Stereotactic Body Radiation Therapy Followed by Surgery in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer
A Early Phase 1 study of Stage II Non-Small Cell Lung Cancer AJCC v7 and Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, sponsored by Roswell Park Cancer Institute.
- Active
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT03348748 is a Early Phase 1 study of Stage II Non-Small Cell Lung Cancer AJCC v7 and Stage IIA Non-Small Cell Lung Carcinoma AJCC v7 that is active but no longer recruiting, run by Roswell Park Cancer Institute. The registered enrollment target is 20 participants, below the 214-participant average among 3 other Stage II Non-Small Cell Lung Cancer AJCC v7 trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03348748, a Early Phase 1 study of Stage II Non-Small Cell Lung Cancer AJCC v7 and Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, is active but no longer recruiting, sponsored by Roswell Park Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot clinical trial studies the effects of stereotactic body radiation therapy followed by surgery in treating patients with stage I-IIIA non-small cell lung cancer. Stereotactic body radiation therapy is a method of radiation that uses imaging to precisely locate a tumor and then deliver very high radiation doses to the tumor site in order to limit normal tissue toxicity or damage.
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Laboratory Biomarker Analysis
- DRUG Stereotactic Body Radiation Therapy
Study Locations (1)
New York
- Roswell Park Cancer Institute - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-12-18 |
| Est. Completion | 2025-12-08 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03348748
The ClinicalTrials.gov registry entry for NCT03348748 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 214-participant average among 3 other Stage II Non-Small Cell Lung Cancer AJCC v7 trials with a reported enrollment target (91% lower). The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Stage II Non-Small Cell Lung Cancer AJCC v7 appearing as the primary indexed condition, and to 3 interventions - of which Quality-of-Life Assessment is the first listed.
NCT03348748 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03348748 about?
NCT03348748 is a clinical study titled "Stereotactic Body Radiation Therapy Followed by Surgery in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer". This pilot clinical trial studies the effects of stereotactic body radiation therapy followed by surgery in treating patients with stage I-IIIA non-small cell lung cancer. Stereotactic body radiation therapy is a method of radiation that uses imaging to precisely locate a tumor and then deliver very...
What is the current status of trial NCT03348748?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2017-12-18. Estimated completion is 2025-12-08.
What conditions does trial NCT03348748 study?
This clinical trial studies the following conditions: Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IB Non-Small Cell Lung Carcinoma AJCC v7.
What interventions are being tested in trial NCT03348748?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Laboratory Biomarker Analysis (OTHER), Stereotactic Body Radiation Therapy (DRUG).
Who is sponsoring clinical trial NCT03348748?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03348748 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage II Non-Small Cell Lung Cancer AJCC v7
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
ACTIVE NOT RECRUITING · Phase 3
-
Image-Guided, Intensity-Modulated Photon or Proton Beam Radiation Therapy in Treating Patients With Stage II-IIIB Non-small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Stage II Non-Small Cell Lung Cancer AJCC v7
All registered trials for this condition
Stage IIA Non-Small Cell Lung Carcinoma AJCC v7
All registered trials for this condition
New York
All trials with a study site in New York
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.